Tag: compass
Janssen submits application for new Xarelto (rivaroxaban) indications for CAD and...
Janssen has submitted a supplemental new drug application to the US Food and Drug Administration (FDA) for two new Xarelto (rivaroxaban) vascular indications: reducing the...
COMPASS study of Janssen’s rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...
